TABLE 1.
Clinical characteristics in different groups.
| Characteristics | Trastuzumab | Trastuzumab+ Lapatinib |
Trastuzumab+ Neratinib |
Trastuzumab+ Tucatinib |
|---|---|---|---|---|
| Sex | ||||
| Female | 26,241 (74.28%) | 961 (91.26%) | 78 (50.65%) | 1,487 (84.20%) |
| Male | 2,196 (6.22%) | 15 (1.42%) | 2 (1.30%) | 87 (4.93%) |
| Unknown | 6,890 (19.50%) | 77 (7.31%) | 74 (48.05%) | 192 (10.87%) |
| Weight(kg) | ||||
| <50 | 992 (2.81%) | 53 (5.03%) | — | 42 (2.38%) |
| 50–100 | 8,047 (22.78%) | 309 (29.34%) | 18 (11.69%) | 318 (18.01%) |
| >100 | 420 (1.19%) | 14 (1.33%) | 1 (0.65%) | 27 (1.53%) |
| Missing | 25,868 (73.22%) | 677 (64.29%) | 135 (87.66%) | 1,379 (78.09%) |
| Age | ||||
| ≤18 | 34 (0.10%) | 1 (0.10%) | — | 5 (0.28%) |
| 19–44 | 3,466 (9.81%) | 122 (11.59%) | 13 (8.44%) | 172 (9.74%) |
| 45–64 | 10,236 (28.98%) | 450 (42.74%) | 40 (25.97%) | 452 (25.59%) |
| 65–74 | 3,716 (10.52%) | 133 (12.63%) | 11 (7.14%) | 189 (10.70%) |
| ≥75 | 1,643 (4.65%) | 49 (4.65%) | 5 (3.25%) | 59 (3.34%) |
| Missing | 16,232 (45.95%) | 298 (28.30%) | 85 (55.19%) | 889 (50.34%) |
| Reporter type | ||||
| Consumer | 6,363 (18.01%) | 501 (47.58%) | 15 (9.74%) | 357 (20.22%) |
| Pharmacist | 2,994 (8.48%) | 33 (3.13%) | 11 (7.14%) | 74 (4.19%) |
| Physician | 16,193 (45.84%) | 388 (36.85%) | 80 (51.95%) | 1,008 (57.08%) |
| Lawyer | 20 (0.06%) | — | — | — |
| Health-professional | 9,388 (26.57%) | 123 (11.68%) | 47 (30.52%) | 327 (18.52%) |
| Unknown | 369 (1.04%) | 8 (0.76%) | 1 (0.65%) | — |
| Outcome | ||||
| Death | 5,138 (14.54%) | 122 (11.59%) | 44 (28.57%) | 148 (8.38%) |
| Life-Threatening | 1,188 (3.36%) | 29 (2.75%) | 5 (3.25%) | 18 (1.02%) |
| Hospitalization | 7,386 (20.91%) | 149 (14.15%) | 30 (19.48%) | 440 (24.92%) |
| Disability | 518 (1.47%) | 5 (0.47%) | — | 14 (0.79%) |
| Congenital anomaly | 49 (0.14%) | 1 (0.09%) | — | — |
| Required intervention | 83 (0.23%) | 1 (0.09%) | — | — |
| Others | 14,767 (41.80%) | 341 (32.38%) | 51 (33.12%) | 668 (37.83%) |
| Missing | 6,198 (17.54%) | 405 (38.46%) | 24 (15.58%) | 478 (27.07%) |
| Top five countries reported | ||||
| | United States | United States | United States | United States |
| | China | Canada | United Kingdom | France |
| | Canada | Japan | Canada | Greece |
| | United Kingdom | Australia | Austria | Germany |
| | Japan | Austria | China | Austria |
| Top-ranked indication | ||||
| | Breast cancer | Breast cancer | Breast cancer metastatic | Breast cancer |